Academia.eduAcademia.edu

Outline

Reply to “Separating neuroethics from neurohype”

2019, Nature Biotechnology

https://doi.org/10.1038/S41587-019-0226-8

Abstract
sparkles

AI

Ienca et al. respond to Wexler's critique regarding the state of neurotechnology, arguing that her assertions about consumer EEG devices and FDA approvals are factually incorrect. They assert the importance of proactive ethical scrutiny and regulatory oversight in the face of advancing neurotechnology, especially considering recent data privacy scandals. The authors emphasize the need for ongoing ethical analysis to prevent history from repeating itself with consumer neurotechnology, advocating for timely reflection and action in addressing ethical implications as technology evolves.

References (9)

  1. Ienca, M., Haselager, P. & Emanuel, E. J. Nat. Biotechnol. 36, 805-810 (2018).
  2. Rostami, M., Golesorkhi, M. & Ekhtiari, H. Basic Clin. Neurosci. 4, 190-208 (2013).
  3. Boto, E. et al. Nature 555, 657-661 (2018).
  4. Price, W. N. II & Cohen, I. G. Nat. Med. 25, 37-43 (2019).
  5. Roy, Y., Hubert, B., Isabela, A., Alexandre, G. & Jocelyn, F. Deep learning-based electroencephalography analysis: a systematic review. Preprint at https://arxiv.org/abs/1901.05498 (2019).
  6. Kahn, J. P., Vayena, E. & Mastroianni, A. C. Proc. Natl Acad. Sci. USA 111, 13677-13679 (2014).
  7. Martinez-Martin, N. AMA J. Ethics 21, 180-187 (2019).
  8. Enserink, M. & Chin, G. Science 347, 490-491 (2015).
  9. Nature 555, 559-560 (2018).